Why Firefly Neuroscience, Inc.’s (AIFF) Stock Is Down 16.19%
As of Tuesday, February 25, Firefly Neuroscience, Inc.’s AIFF share price has dipped by 16.19%, which has investors questioning if this is right time to buy.Omar Beirat
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Firefly Neuroscience, Inc., an artificial intelligence company, develops, markets, and distributes medical devices and technologies that allow high-resolution visualization and evaluation of the complex neurophysiological interconnections of the human brain in North America. The company offers the Evoke System, a system used to perform electroencephalographic (EEG) and event-related potential (ERP) assessments, which are analyzed by its cloud-based platform and returned as structured reports designed to support clinical decision-making for various diseases, including depression, anxiety, ADHD, PTSD, MCI, dementia, Parkinson's disease, bipolar disorder, schizophrenia, schizoaffective disorder, ASD, and traumatic brain injury. It serves clinicians. Firefly Neuroscience, Inc. was founded in 2006 and is based in Kenmore, New York.
Commentary & Analysis
Why Firefly Neuroscience, Inc.’s (AIFF) Stock Is Down 15.29%
As of Thursday, February 20, Firefly Neuroscience, Inc.’s AIFF share price has dipped by 15.29%, which has investors questioning if this is right time to buy.Aneeqa Nadeem
Why Firefly Neuroscience, Inc.’s (AIFF) Stock Is Down 41.72%
As of Friday, February 14, Firefly Neuroscience, Inc.’s AIFF share price has dipped by 41.72%, which has investors questioning if this is right time to buy.Tudor Pop
Why Firefly Neuroscience, Inc.’s (AIFF) Stock Is Up 19.20%
As of Thursday, February 13, Firefly Neuroscience, Inc.’s AIFF share price has surged by 19.20%, which has investors questioning if this is right time to sell.Aneeqa Nadeem
Why Firefly Neuroscience, Inc.’s (AIFF) Stock Is Up 54.40%
As of Wednesday, February 12, Firefly Neuroscience, Inc.’s AIFF share price has surged by 54.40%, which has investors questioning if this is right time to sell.Aneeqa Nadeem
Financial Summary
| Share Statistics | AIFF | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $15.7 | $181.1 | 9% |
|
| Shares Out (Mil) | 16.2 | 47.9 | 27% |
|
| Institutional Ownership | 64.9% | 78.5% | 40% |
|
| Float (Mil) | 14.2 | 40.1 | 24% |
|
| Beta | na | 1.23 | na |
|
| Avg Daily Volume (000s) | 109 | 205 | 37% |
|
| Price Change (52-week) |
(64.2%) | 41.7% | 11% |
|
| Growth | AIFF | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.7% | na |
|
| Net Income (5yr) | na | (1.0%) | na |
|
| EPS (5yr) | na | 15.5% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.5%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | AIFF | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $192 | 3% |
|
| Net Income (TTM) (Mil) | ($9) | ($9) | 30% |
|
| EPS (TTM) | ($0.663) | ($0.500) | 25% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | $8 | 21% |
|
| Net Cash Flow (TTM) (Mil) | ($6) | ($4) | 33% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $14 | 0% |
|
| Enterprise Value (Q1) (Mil) | $14 | $215 | 9% |
|
| Valuation | AIFF | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.77 | 1.17 | 47% |
|
| P/E | na | 35.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 2.0 | na |
|
| Ratios | AIFF | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 52.0% | 61.6% | 64% |
|
| Net Margin | (565.4%) | (29.3%) | 1% |
|
| ROA | (77.0%) | (21.9%) | 7% |
|
| ROE | (131.4%) | (1.4%) | 7% |
|
| Liabilities to Assets | 22.6% | 33.3% | 15% |
|
| F-Score | 4 | 4 | 34% |
|
Firefly Neuroscience, Inc. did not pass any screens on 7/30/2026.
